IKT - Inhibikase Therapeutics, Inc. News

Inhibikase Therapeutics Q2 EPS $(0.11), Inline

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which met the an

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activi

WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In

ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT

ADAR1 Capital Management LLC reduced its stake in Inhibikase Therapeutics, Inc. (NASDAQ: IKT) by 18.

Inhibikase Therapeutics Says FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-00

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment o

WILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In

Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Ma

US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading

Inhibikase Therapeutics Sells 25M Common Shares To RA Capital Management Through At-The-Market Facil

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Faci

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“In

Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Ta

Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating an

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the a

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activit

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inh

Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatme

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., April 03, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I

Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.10) per share which beat the a

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“I

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February

Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) was the target of a significant increa

Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Ta

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:I

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

Inhibikase Therapeutics (NYSE: IKT - Get Free Report) and Big Cypress Acquisition (OTCMKTS:BCYP - Ge

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts

Inhibikase Therapeutics, Inc. (NASDAQ: IKT - Get Free Report) has been given a consensus recommendat

Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)

Big Cypress Acquisition (OTCMKTS:BCYP - Get Free Report) and Inhibikase Therapeutics (NYSE: IKT - Ge

B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Tar

B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IK

Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey

Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Fre

12 Health Care Stocks Moving In Friday's Intraday Session

HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) w

Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

12 Health Care Stocks Moving In Wednesday's After-Market Session

Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)

Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Fre

Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program

On December 19, 2025, Inhibikase Therapeutics, Inc. (the "Company") filed with the Securitie

Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Pr

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT

Financial Analysis: Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN)

Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Fre

12 Health Care Stocks Moving In Friday's Pre-Market Session

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Fu

WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“In

Inhibikase Therapeutics Announces Common Stock Offering; Terms Not Disclosed

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ("Inhibikase" or "Company"), a clinical-

12 Health Care Stocks Moving In Thursday's After-Market Session

Inhibikase Therapeutics Announces Plans To Advance Its PAH Therapeutic Candidate, IKT-001, Into A Gl

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-s

Inhibikase Therapeutics Q3 EPS $(0.13), Inline

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the an

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Inhibikase Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate

Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Inhibikase Therapeutics Files For Mixed Shelf Of Up To $300M

https://www.sec.gov/Archives/edgar/data/1750149/000119312525143738/d77556ds3.htm